Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05847192 · ClinicalTrials.gov registry record
Tau Networks in Psychotic Alzheimer's Disease
A clinical trial of Alzheimer Disease and Alzheimer Disease With Delusions, sponsored by Northwell Health.
- Recruiting
- Registry status
- 91
- Enrollment target
- 1
- Study location
NCT05847192 is a study of Alzheimer Disease and Alzheimer Disease With Delusions that is actively recruiting participants, run by Northwell Health. The registered enrollment target is 91 participants, below the 2,750-participant average among 306 other Alzheimer Disease trials with a reported enrollment target (97% lower). The trial reports 1 study location across 1 state.
The verdict
NCT05847192, a study of Alzheimer Disease and Alzheimer Disease With Delusions, is actively recruiting participants, sponsored by Northwell Health.
- RECRUITING
- Registry status
- 91 participants
- Enrollment target
- 1
- Study location
Study Summary
This research project aims to understand the brain mechanisms behind the manifestation of psychotic symptoms in Alzheimer´s disease (AD), and nature of the unique relationship with tau pathology. Amongst the cognitive manifestations of psychosis are impairments related to frontal circuits (social cognition, working memory and executive function deficits). The investigator's previous work suggests a role of tau pathology (one of the hallmarks of AD neuropathology) in the manifestation of psychosis in AD. However, the cerebral mechanisms that underly this association remain poorly understood. The overarching aim of the study is is to investigate the mechanisms by which tau network pathology may promote the presentation of psychosis in AD.
Conditions Studied
Interventions
- DIAGNOSTIC_TEST [18F]-PI2620 PET scan
Study Locations (1)
New York
- The Feinstein Institutes for Medical Research - Manhasset
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 91 participants |
| Start Date | 2023-04-13 |
| Est. Completion | 2029-12-31 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05847192
The ClinicalTrials.gov registry entry for NCT05847192 describes a study currently listed as recruiting, categorized as an unspecified phase. The registered enrollment target is 91 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 2,750-participant average among 306 other Alzheimer Disease trials with a reported enrollment target (97% lower). The listed sponsor is Northwell Health, which has 370 total studies on file at ClinicalTrials.gov.
The record links to 3 conditions, with Alzheimer Disease appearing as the primary indexed condition, and to 1 intervention - of which [18F]-PI2620 PET scan is the first listed.
NCT05847192 reports 1 study location spanning 1 distinct geographic area - top geographies include New York.
Frequently Asked Questions
What is clinical trial NCT05847192 about?
NCT05847192 is a clinical study titled "Tau Networks in Psychotic Alzheimer's Disease". This research project aims to understand the brain mechanisms behind the manifestation of psychotic symptoms in Alzheimer´s disease (AD), and nature of the unique relationship with tau pathology. Amongst the cognitive manifestations of psychosis are impairments related to frontal circuits (social co...
What is the current status of trial NCT05847192?
This trial is currently recruiting. The enrollment target is 91 participants. The study started on 2023-04-13. Estimated completion is 2029-12-31.
What conditions does trial NCT05847192 study?
This clinical trial studies the following conditions: Alzheimer Disease, Alzheimer Disease With Delusions, Alzheimer Disease With Psychosis.
What interventions are being tested in trial NCT05847192?
The interventions under investigation include: [18F]-PI2620 PET scan (DIAGNOSTIC_TEST).
Who is sponsoring clinical trial NCT05847192?
This trial is sponsored by Northwell Health, which has 370 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05847192 being conducted?
This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Alzheimer Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Phase 3 Study to Evaluate the Safety and Efficacy of KarXT + KarX-EC for the Treatment of Agitation Associated With Alzheimer's Disease (ADAGIO-2)
RECRUITING · Phase 3
-
Sex-Specific Effects of Endocrine Disruption on Aging and Alzheimer's Disease
RECRUITING · Phase 4
-
Systemic and Central Inflammation in AD
RECRUITING · Phase 2
-
I-CARE 2: Mobile Telehealth to Reduce Alzheimer'S-related Symptoms
RECRUITING · NA
-
Autologous Activated Adipose-derived Stem Cells (RB-ADSC) Injected Directly Into the Brain for Mild to Moderate Alzheimer's Disease
RECRUITING · Phase 1
-
Cognitive Neurology Unit Clinical Registry
RECRUITING
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.